Johnson & Johnson (NYSE:JNJ) is one of the The 15 Best Stocks to Buy According to Billionaire Ray Dalio. Johnson & Johnson (NYSE:JNJ) has been in Bridgewater Associates’ 13F portfolio for more than a decade and a half. The fund has maintained a small position in the company since early 2011, increasing this stake to…
Johnson & Johnson (NYSE:JNJ) is one of The most profitable blue-chip stocks to invest in now. On March 11, Citi raised its price target on Johnson & Johnson (NYSE:JNJ) to $274 from $250, while maintaining a Buy rating on the stock. The company told investors in a research note that it adjusted price targets on…
We recently published 10 Stocks on Jim Cramer’s Radar. Johnson & Johnson (NYSE:JNJ) is one of the stocks that’s on Jim Cramer’s radar. Shares of pharmaceutical giant Johnson & Johnson (NYSE:JNJ) are up 53% over the past year and 15% so far this year. In recent months, Cramer has become optimistic about the company. Some…
Johnson & Johnson (NYSE:JNJ) is one of the shares Jim Cramer shared his thoughts on. Cramer noted how money managers are betting on an economic slowdown and commented: “So let’s talk about Procter & Gamble and then let’s talk about a pharmaceutical company, J&J. Now, here are two companies that have products that you buy,…
Dividend stocks are the best option for investors looking for steady passive income. These are companies with stable cash flows, healthy balance sheets, and a long history of rewarding shareholders with consistent dividends. Here are two solid dividend stocks that excel at providing consistent income and long-term stability, even in volatile markets. Johnson & Johnson…
Kimberly-Clark agreed to acquire Johnson & Johnson (J&J) consumer health spinoff Kenvue for $48.7 billion. Kimberly-Clark, one of the largest U.S. consumer health companies, said it would acquire all of Kenvue’s common stock, creating a conglomerate that will generate annual revenue of $32 billion. Under the deal, shareholders of Kenvue, a company J&J spun off…
Volatility comes and goes… but despite that, some companies continue to pay consistently. The Dividend Kings are the elite group of companies that have offered shareholders 50 years of consistent dividend growth. These companies have weathered recessions, periods of inflation, and various market uncertainties while achieving stable, long-term payouts. This is the kind of consistency…
August saw a reversal of fortune for short sellers, who had faced two consecutive months of losses. The pause in the steady rise of US stocks provided the backdrop for this change, as outlined in the latest analysis from data and analytics company Ortex. Over the past month, bearish investors collectively pocketed a substantial $14.8…
Johnson & Johnson (J&J) is exiting the orthopedics business, a major strategic shift for one of the world’s largest consumer health and medical technology companies. The decision to shed its orthopedic implants and related surgical products marks a turning point that could reshape both the company and the broader market for joint replacements, trauma devices…
In 1894, Johnson & Johnson (JNJ) began selling talcum powder under the brand name Johnson’s Baby Powder. Over the years, it became a staple in many homes. However, concerns have been raised about the safety of talc, with accusations linking it to cancer. Despite these challenges, the company reported its first quarter earnings, showing a…
